MCID: PRT038
MIFTS: 51

Protein-Energy Malnutrition

Categories: Metabolic diseases

Aliases & Classifications for Protein-Energy Malnutrition

MalaCards integrated aliases for Protein-Energy Malnutrition:

Name: Protein-Energy Malnutrition 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:11801
ICD10 33 E46
ICD9CM 35 263.9
MeSH 44 D011502
NCIt 50 C34952
UMLS 73 C0033677

Summaries for Protein-Energy Malnutrition

MalaCards based summary : Protein-Energy Malnutrition is related to protein-losing enteropathy and keratomalacia, and has symptoms including cachexia and emaciation. An important gene associated with Protein-Energy Malnutrition is ALB (Albumin), and among its related pathways/superpathways are IL-1 Family Signaling Pathways and Dilated cardiomyopathy (DCM). The drugs Morphine and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include prostate, liver and brain, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 76 Protein–energy malnutrition (PEM) refers to a form of malnutrition which is defined as a range of... more...

Related Diseases for Protein-Energy Malnutrition

Diseases related to Protein-Energy Malnutrition via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 protein-losing enteropathy 30.8 ALB CD79A
2 keratomalacia 30.7 TF TTR
3 ancylostomiasis 30.6 CP TF
4 marasmus 30.4 ALB CD79A TF TTR
5 liver cirrhosis 30.3 ALB GPT TF
6 kwashiorkor 30.1 ALB GPT TF TTR
7 anorexia nervosa 29.9 IGF1 LEP TTR
8 burns 29.6 ALB TNF TTR
9 peritonitis 29.6 ALB IL6 TNF
10 deficiency anemia 29.4 ALB CP IL6 TF
11 diarrhea 29.4 ALB CD79A TNF
12 meningitis 29.1 ALB IL6 TNF
13 viral hepatitis 29.0 ALB GPT TNF
14 rheumatoid arthritis 28.5 CD79A IL6 TNF TTR
15 alcoholic hepatitis 28.1 ALB GPT IL6 TNF
16 fatty liver disease 27.8 GPT IL6 LEP TNF
17 chronic kidney failure 27.5 ALB CD79A IGF1 IL6 LEP TF
18 liver disease 27.0 ALB CP GPT LEP TF TNF
19 diabetes mellitus 27.0 ALB CP IGF1 IL6 LEP TNF
20 diabetes mellitus, noninsulin-dependent 26.8 ALB GPT IGF1 IL6 LEP TNF
21 paramyloidosis 10.9 ALB TTR
22 cork-handlers' disease 10.8 ALB CD79A
23 ostertagiasis 10.8 ALB CD79A
24 chronic ulcer of skin 10.8 ALB TTR
25 dermatitis, atopic, 3 10.8 ALB CD79A
26 decubitus ulcer 10.8 ALB TTR
27 median rhomboid glossitis 10.8 TF TTR
28 carotenemia 10.8 CD79A TTR
29 root caries 10.8 ALB CD79A
30 meningitis and encephalitis 10.8 ALB CP
31 aleutian mink disease 10.8 ALB TTR
32 parotitis 10.8 ALB CD79A
33 blepharochalasis 10.8 CD79A TTR
34 orthostatic proteinuria 10.7 ALB CD79A
35 chronic graft versus host disease 10.7 ALB CD79A
36 diffuse glomerulonephritis 10.7 ALB CD79A
37 hyperthyroxinemia 10.7 ALB TTR
38 focal dermal hypoplasia 10.7 ALB CD79A
39 ulcerative blepharitis 10.7 CD79A CP
40 non-secretory myeloma 10.7 ALB CD79A
41 ariboflavinosis 10.6 ALB TF
42 hypochromic microcytic anemia 10.6 CP TF
43 amyloid tumor 10.6 CD79A TTR
44 autonomic nervous system disease 10.6 ALB TTR
45 euthyroid sick syndrome 10.5 ALB IL6
46 glossitis 10.5 IL6 TTR
47 testicular yolk sac tumor 10.5 ALB TF TTR
48 pure red-cell aplasia 10.5 ALB TF
49 polyclonal hypergammaglobulinemia 10.5 CD79A IL6
50 capillary leak syndrome 10.5 ALB IL6

Comorbidity relations with Protein-Energy Malnutrition via Phenotypic Disease Network (PDN): (show top 50) (show all 153)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Pancreatitis Acute Vascular Insufficiency of Intestine
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Alzheimer Disease Anorexia Nervosa
Anxiety Atrophic Gastritis
Bacteremia 2 Biliary Tract Neoplasm
Bronchiectasis Bronchitis
Bronchopneumonia Bullous Pemphigoid
Candidiasis Cardiac Arrest
Cecal Benign Neoplasm Celiac Disease 1
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Cholangitis
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Kidney Failure
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Ulcer of Skin Chylomicron Retention Disease
Colorectal Cancer Conjunctivitis
Crohn's Disease Cystitis
Decubitus Ulcer Deficiency Anemia
Dental Caries Dermatomycosis
Disseminated Intravascular Coagulation Duodenum Cancer
Dyskinesia of Esophagus Dysthymic Disorder

Graphical network of the top 20 diseases related to Protein-Energy Malnutrition:



Diseases related to Protein-Energy Malnutrition

Symptoms & Phenotypes for Protein-Energy Malnutrition

UMLS symptoms related to Protein-Energy Malnutrition:


cachexia, emaciation

MGI Mouse Phenotypes related to Protein-Energy Malnutrition:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 IL6 LEP PIGR TF TNF CD79A
2 homeostasis/metabolism MP:0005376 9.85 IL6 LEP PIGR TF ALB TNF
3 adipose tissue MP:0005375 9.72 IL6 LEP TNF CP IGF1
4 liver/biliary system MP:0005370 9.43 IL6 LEP ALB TNF CD79A CP
5 neoplasm MP:0002006 9.1 IL6 LEP ALB TNF CD79A IGF1

Drugs & Therapeutics for Protein-Energy Malnutrition

Drugs for Protein-Energy Malnutrition (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
2
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
3
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
4
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 52485-79-7 40400 644073
5
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
6
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
7 Analgesics Phase 4,Phase 3,Phase 2
8 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
9 Analgesics, Opioid Phase 4,Phase 3,Phase 2
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2
11 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
12 Narcotics Phase 4,Phase 3,Phase 2
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
14 Antimetabolites Phase 4,Phase 2,Phase 1
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
17 Cyclooxygenase Inhibitors Phase 4
18 Narcotic Antagonists Phase 4,Phase 3
19 Opiate Alkaloids Phase 4
20 HIV Protease Inhibitors Phase 4,Phase 2
21
protease inhibitors Phase 4,Phase 2
22 Gastrointestinal Agents Phase 4,Phase 2
23 Cystatins Phase 4
24 Anticholesteremic Agents Phase 4
25 Bile Acids and Salts Phase 4
26 Cathartics Phase 4
27 Colesevelam Hydrochloride Phase 4
28 Glucagon-Like Peptide 1 Phase 4
29 Hypolipidemic Agents Phase 4
30 Laxatives Phase 4
31 Lipid Regulating Agents Phase 4
32 Liver Extracts Phase 4,Not Applicable
33 cysteine Nutraceutical Phase 4,Not Applicable
34 isoleucine Nutraceutical Phase 4
35 leucine Nutraceutical Phase 4
36 valine Nutraceutical Phase 4
37
Acetaminophen Approved Phase 3,Phase 2 103-90-2 1983
38
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 9552079 2713
39
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
40
Lubiprostone Approved, Investigational Phase 3 136790-76-6 656719
41
Sodium oxybate Approved Phase 3 502-85-2 5360545
42
Hydrocodone Approved, Illicit Phase 3 125-29-1 5284569
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Dermatologic Agents Phase 3,Phase 2
45 Adjuvants, Anesthesia Phase 3,Phase 2
46 Anesthetics Phase 3,Phase 2
47 Anti-Infective Agents, Local Phase 3
48 Chlorhexidine gluconate Phase 3
49 Disinfectants Phase 3,Not Applicable
50 Emollients Phase 3

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Egg Albumin-Based Protein Supplement Versus Renal-specific Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
2 Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial Completed NCT02152592 Phase 4 PCM/Oxy1;PCM/Oxy2
3 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
4 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS Recruiting NCT02276066 Phase 4 Iohexol
5 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
6 Extended Duration Artemether-lumefantrine Treatment for Malaria in Children Recruiting NCT03453840 Phase 4 Artemether-lumefantrine
7 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Active, not recruiting NCT02837302 Phase 4 Livact
8 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4 morphine sulfate and naltrexone hydrochloride (EMBEDA)
9 Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds Unknown status NCT00755989 Phase 3 morphine topical gel;placebo
10 Post-Approval Clinical Trial of the PCM® Cervical Disc Completed NCT01905930 Phase 3
11 PCM Cervical Disc System Completed NCT00578812 Phase 3
12 Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer Completed NCT01875393 Phase 3 TOOKAD® Soluble
13 Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Completed NCT01310894 Phase 3 TOOKAD® Soluble
14 Newborn Kit to Save Lives and Brains in Kenya Completed NCT02208960 Phase 3
15 Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients Completed NCT00561093 Phase 3 pentoxiphylline;Placebo pill imitating pentoxiphylline
16 Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone Completed NCT00597428 Phase 3 Lubiprostone;Placebo
17 Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia. Completed NCT00423605 Phase 3 Xyrem®
18 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia Completed NCT00371137 Phase 3 Xyrem®;Placebo
19 Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain Completed NCT00312572 Phase 3 Buprenorphine transdermal patch
20 Paracetamol for Intrapartum Analgesia Unknown status NCT02578251 Phase 2 Paracetamol;Pethidine
21 Whole Body Cooling Using Phase Changing Material Unknown status NCT01138176 Phase 1, Phase 2
22 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
23 Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery Unknown status NCT00563160 Phase 2 gemcitabine, carboplatin
24 Violence and Stress Assessment (ViStA) Project to Improve Post Traumatic Stress Disorder Management in Primary Care Completed NCT01401101 Phase 2
25 Collection of Transplant Stem Cells for Plasma Cell Myeloma Completed NCT01547806 Phase 2 Filgrastim;Plerixafor
26 Study Using WST11 in Patients With Localized Prostate Cancer Completed NCT00975429 Phase 2 WST11;WST11
27 Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer Completed NCT00946881 Phase 1, Phase 2 WST 11 -mediated -VTP
28 Study of WST11 in Patients With Localized Prostate Cancer Completed NCT00707356 Phase 2 WST11
29 Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men Completed NCT01294319 Phase 2 Mifepristone;Placebo;Spironolactone;Combined;Dexamethasone
30 PCM-075 in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML). Recruiting NCT03303339 Phase 1, Phase 2 PCM-075;Cytarabine;Decitabine
31 PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting NCT03414034 Phase 2 PCM-075;Abiraterone;Prednisone
32 Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. Recruiting NCT03315754 Phase 2 TOOKAD Soluble 4 mg/kg
33 Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma Terminated NCT00557830 Phase 2 Sorafenib Escalated Dose;Sorafenib Standard Dose
34 Acceptability and Efficacy of 'Fish Surimi Peptide' in Under Five Children Suffering From Moderate Acute Malnutrition Completed NCT02272543 Phase 1
35 Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1 LOXO-292
36 A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer Terminated NCT00779311 Phase 1 sorafenib;bevacizumab;mFOLFOX6 regimen
37 Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project) Unknown status NCT02273206 Not Applicable
38 The Impact of Perioperational Malnutrition on the Cost on Gastroenterological Cancer Patients Unknown status NCT00987883
39 Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients Completed NCT00135590 Not Applicable
40 Clinical Performance of the Embrace Isothermal Mattress Completed NCT01425086
41 Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Completed NCT01873963
42 Study of Antioxidants and Oxidants in Malnourished Children Completed NCT00069134 Not Applicable
43 Enhancing HIV Prevention by Using Behavioral Intervention Among HIV-Infected Men Completed NCT00231972 Not Applicable
44 Energy Dense Formula to People Living in Old Peoples Home Completed NCT01259999 Not Applicable
45 aCGH Impacts Survival in Plasma Cell PTLD Completed NCT02984215
46 Role of Nutrition in Patients Over 75 Years of Age With Stroke Completed NCT02856009 Not Applicable
47 Bioelectrical Impedance Vector Analysis in Cirrhotic Patients Completed NCT01603953
48 Incomes of Nutritional Support Modalities in Hemodialysis Patients With Severe Malnutrition Completed NCT03484481
49 Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer Completed NCT01721343 Not Applicable
50 Visibility of Lesion Characteristics With Phase Contrast Mammography Completed NCT00467727 Not Applicable

Search NIH Clinical Center for Protein-Energy Malnutrition

Cochrane evidence based reviews: protein-energy malnutrition

Genetic Tests for Protein-Energy Malnutrition

Anatomical Context for Protein-Energy Malnutrition

MalaCards organs/tissues related to Protein-Energy Malnutrition:

41
Prostate, Liver, Brain, Bone, Thyroid, Kidney, Testes

Publications for Protein-Energy Malnutrition

Articles related to Protein-Energy Malnutrition:

(show top 50) (show all 540)
# Title Authors Year
1
Identifying reliable predictors of protein-energy malnutrition in hospitalized frail older adults: A prospective longitudinal study. ( 29579571 )
2018
2
Protein-Energy Malnutrition Exacerbates Stroke-Induced Forelimb Abnormalities and Dampens Neuroinflammation. ( 29397529 )
2018
3
Why Is the Skeleton Still in the Hospital Closet? A Look at the Complex Aetiology of Protein-Energy Malnutrition and Its Implications for the Nutrition Care Team. ( 29300418 )
2018
4
Prospective associations of poor diet quality with long-term incidence of protein-energy malnutrition in community-dwelling older adults: the Health, Aging, and Body Composition (Health ABC) Study. ( 29529142 )
2018
5
Honey can repairing damage of liver tissue due to protein energy malnutrition through induction of endogenous stem cells. ( 28717326 )
2017
6
Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in mice. ( 28860040 )
2017
7
Protein blend ingestion before allogeneic stem cell transplantation improves protein-energy malnutrition in patients with leukemia. ( 28964569 )
2017
8
Genetic Engineering: A Possible Strategy for Protein-Energy Malnutrition Regulation. ( 28828714 )
2017
9
An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition. ( 28934453 )
2017
10
A systematic review and meta-analysis of the criterion validity of nutrition assessment tools for diagnosing protein-energy malnutrition in the older community setting (the MACRo study). ( 29102322 )
2017
11
The Arid Melancholy-Netherton Syndrome With Protein Energy Malnutrition. ( 27190931 )
2016
12
Protein-energy malnutrition is frequent and precocious in children with cri du chat syndrome. ( 26872355 )
2016
13
Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly population. ( 27456231 )
2016
14
Protein energy malnutrition associates with different types of hearing impairments in toddlers: Anemia increases cochlear dysfunction. ( 27240492 )
2016
15
Protein-energy malnutrition in the rehabilitation setting: Evidence to improve identification. ( 26921933 )
2016
16
Does protein energy malnutrition affect the outcome in Tunisian cirrhotic patients? ( 27532543 )
2016
17
Serum hyaluronic acid predicts protein-energy malnutrition in chronic hepatitis C. ( 27311000 )
2016
18
Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis. ( 27862791 )
2016
19
Factors Associated With Protein-energy Malnutrition in Chronic Liver Disease: Analysis Using Indirect Calorimetry. ( 26765430 )
2016
20
Protein-energy malnutrition at mid-adulthood does not imprint long-term metabolic consequences in male rats. ( 26133298 )
2015
21
Serum vitamin D status in children with protein-energy malnutrition admitted to a national referral hospital in Uganda. ( 26346815 )
2015
22
Leucine Supplementation Improves Acquired Growth Hormone Resistance in Rats with Protein-Energy Malnutrition. ( 25909895 )
2015
23
Protein-energy malnutrition: a risk factor for various ailments. ( 24915388 )
2015
24
Evaluation of dental age in protein energy malnutrition children. ( 26538919 )
2015
25
Seroprevalence rate of Poliovirus antibodies among the Healthy and Protein Energy Malnutrition children. ( 26101500 )
2015
26
Protein Energy Malnutrition during Vaccination Has Limited Influence on Vaccine Efficacy but Abolishes Immunity if Administered during Mycobacterium tuberculosis Infection. ( 25754202 )
2015
27
Protein-Energy Malnutrition Causes Deficits in Motor Function in Adult Male Rats. ( 26423735 )
2015
28
Protein Energy-Malnutrition: Does the In Vitro Zinc Sulfate Supplementation Improve Chromosomal Damage Repair? ( 25262017 )
2014
29
Free radicals and antioxidant status in protein energy malnutrition. ( 24790610 )
2014
30
Protein energy malnutrition increases arginase activity in monocytes and macrophages. ( 25392710 )
2014
31
Maternal protein-energy malnutrition during early pregnancy in sheep impacts the fetal ornithine cycle to reduce fetal kidney microvascular development. ( 25077559 )
2014
32
Prevalence of protein-energy malnutrition in hospital patients over 75 years of age admitted for hip fracture. ( 24998085 )
2014
33
Protein energy malnutrition in India: the plight of our under five children. ( 24791240 )
2014
34
Protein-energy Malnutrition in Goitrous Schoolchildren of Isfahan, Iran. ( 24932384 )
2014
35
Determinants of protein-energy malnutrition in community dwelling older adults: A systematic review of observational studies. ( 25257179 )
2014
36
Protein-energy malnutrition developing after global brain ischemia induces an atypical acute-phase response and hinders expression of GAP-43. ( 25259609 )
2014
37
Missed opportunities in the diagnosis and management of protein energy malnutrition among children under 5 years in Wakiso district, Uganda. ( 25035810 )
2013
38
Acquired protein energy malnutrition in glutaric acidemia. ( 23330977 )
2013
39
Effect of a probiotic fermented milk on the thymus in Balb/c mice under non-severe protein-energy malnutrition. ( 23286742 )
2013
40
A narrative review of recent progress in understanding the relationship between tuberculosis and protein energy malnutrition. ( 23942176 )
2013
41
Rutin (quercetin rutinoside) induced protein-energy malnutrition in chronic kidney disease, but quercetin acted beneficially. ( 23876017 )
2013
42
Hematologic and Bone Marrow Changes in Children with Protein-Energy Malnutrition. ( 23987917 )
2013
43
Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice. ( 22949306 )
2013
44
Cystic fibrosis: from protein-energy malnutrition to obesity with dyslipidemia. ( 24800027 )
2013
45
Porcine placenta mitigates protein-energy malnutrition-induced fatigue. ( 24035056 )
2013
46
Protein-energy malnutrition induces an aberrant acute-phase response and modifies the circadian rhythm of core temperature. ( 23855272 )
2013
47
Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice. ( 24200975 )
2013
48
A comparison of the full Mini Nutritional Assessment, short-form Mini Nutritional Assessment, and Subjective Global Assessment to predict the risk of protein-energy malnutrition in patients on peritoneal dialysis: a cross-sectional study. ( 23000089 )
2013
49
Relation of oxidative stress, zinc and alkaline phosphatase in protein energy malnutrition. ( 23373727 )
2013
50
Effect of early childhood protein-energy malnutrition on permanent dentition dental caries. ( 24255941 )
2013

Variations for Protein-Energy Malnutrition

Expression for Protein-Energy Malnutrition

Search GEO for disease gene expression data for Protein-Energy Malnutrition.

Pathways for Protein-Energy Malnutrition

GO Terms for Protein-Energy Malnutrition

Cellular components related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ALB CP IGF1 IL6 LEP PIGR
2 endoplasmic reticulum lumen GO:0005788 9.46 ALB CP IL6 TF
3 extracellular space GO:0005615 9.32 ALB CP GPT IGF1 IL6 LEP

Biological processes related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 ALB IGF1 IL6 LEP
2 post-translational protein modification GO:0043687 9.73 ALB CP IL6 TF
3 positive regulation of MAPK cascade GO:0043410 9.72 IGF1 IL6 LEP
4 platelet degranulation GO:0002576 9.67 ALB IGF1 TF
5 regulation of signaling receptor activity GO:0010469 9.65 IGF1 IL6 LEP TNF TTR
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 IGF1 IL6 LEP
7 positive regulation of cytokine production GO:0001819 9.57 LEP TNF
8 positive regulation of JAK-STAT cascade GO:0046427 9.56 IL6 LEP
9 positive regulation of chemokine production GO:0032722 9.54 IL6 TNF
10 leukocyte tethering or rolling GO:0050901 9.52 LEP TNF
11 positive regulation of insulin receptor signaling pathway GO:0046628 9.51 IGF1 LEP
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.5 IGF1 IL6 TNF
13 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.48 IGF1 TNF
14 negative regulation of glucose import GO:0046325 9.46 LEP TNF
15 bone mineralization involved in bone maturation GO:0035630 9.37 IGF1 LEP
16 retina homeostasis GO:0001895 9.33 ALB PIGR TF
17 negative regulation of lipid storage GO:0010888 9.13 IL6 LEP TNF
18 cellular protein metabolic process GO:0044267 9.1 ALB CP IGF1 IL6 TF TTR

Molecular functions related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 IGF1 LEP TTR

Sources for Protein-Energy Malnutrition

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....